The Life Sciences Report
Notable Quotes
"Initial interim data from the Phase 1/2 study with STEM's HuCNS-SC cells in geographic atrophy age-related macular degeneration were extraordinarily encouraging." (7/31/14) StemCells Inc. - The Life Sciences Report Interview with Christopher James More >
"We are very excited about RNN; it's an early-stage oncology company with multiple shots on goal." (7/31/14) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Christopher James More >
"Watch out for NEO; it is significantly undervalued given the opportunities that lie ahead." (7/24/14) NeoGenomics Laboratories - The Life Sciences Report interview with Debjit Chattopadhyay More >
"We feel RXII has largely been ignored by investors, but has potential." (7/10/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Reni Benjamin More >
"Shiseido's investment in a collaboration with RP is a form of validation for the company." (7/17/14) RepliCel Life Sciences Inc. - The Life Sciences Report interview with Alan Leong More >
Companies
| Last: | |||
| Change: | Change(%): | ||
| Volume: | Open: | ||
| High: | Low: | ||
| 52Wk High: | 52Wk Low: | ||
Celldex Therapeutics Inc.TICKER: CLDX:NASDAQ
|
A summary of Expert Comments about Celldex Therapeutics Inc. is currently unavailable. You can find Expert Comments on companies similar to Celldex Therapeutics Inc. by clicking on the links below.